A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma
Interventions: DRUG: ABT-888|DRUG: Temozolomide
Sponsor: AbbVie